Enterococcus faecium L-3 in Eradication of Helicobacter pylori: In-vivo and In-vitro

Abstract

Usage of probiotics as component of anti-helicobacter therapy had been recently approved as a promising trend in the clinical practice. Over the years, we observed high efficacy of probiotic multi bacteriocinogenic strain Enterococcus faecium L-3 as an additional component of the standard triple therapy in eradication of Helicobacter pylori (H.p.) in patients with chronic gastritis associated with H. pylori infection. The cultivation of H.p. in the presence of live probiotic cultures of E. faecium L-3, Escherichia coli M17, Lactobacillus plantarum 8R-A3 showed superior antagonistic activity of enterococci relatively to other tested bacteria. The anti-helicobacter activity of chemically synthesized enterococcal bacteriocins EntB and Enxβ were studied using 6 strains of H. pylori. The strain-specific action of synthetic enterocins used was determined. Testing of sensitivity of H. pylori. to probiotics and their metabolites in vitro would be important for the selection and prediction of the clinical effectiveness of probiotics as well as development of new anti-helicobacter drugs and lines of combined therapies based on enterocins.

Probiotics and autoprobiotics for treatment of Helicobacter pylori infection

“…In an in vitro study conducted by our team, it was observed that the inhibition of H. pylori growth occurred in 50% of cases in contact with a probiotic based on Bacillus subtilis , 78.6% of cases in contact with Enterococcus faecium strain L-3, and 64% of cases in contact with a combination of Bifidobacterium longum and Enterococcus faecium [ 83 ]. In an in vivo study, monotherapy with Enterococcus faecium strain L-3 in patients with chronic gastritis associated with H. pylori showed an eradication rate of 39%[ 84 ].…”

The role of probiotics in <i>Helicobacter pylori</i> eradication therapy regimens: current evidence of eff ectiveness

“…При этом в эксперименте in vivo эта способность E. faecium L3. была существенно выше, чем у Escherichia coli M17 и Lactobacillus plantarum 8R-A3 [44]. В недавнем исследовании, представленном итальянскими микробиологами была показана бактериостатическая и бактерицидная активность против H. pylori пяти штаммов пробиотиков, при этом наибольшие ингибирующие свой ства выявлены у L. casei, L. paracasei и L. acidofi lus [45].…”